

Bibliography

1. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, et al. Clues to the pathogenesis of familial colorectal cancer. *Science* 1993; 260:812-816.
2. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colo-rectal cancer (HNPCC) syndrome. *Int J Cancer* 1995; 64:430-433.
3. Abal M, Planaguma J, Gil-Moreno A, Monge M, Gonzalez M, Baro T, Garcia A, Castellvi J, Ramon Y, Cajal S, Xercavins J, Alameda F, Reventos J. Molecular pathology of endometrial carcinoma: transcriptional signature in endometroid tumors. *Histol Histopathol* 2006; 21(2):197-204.
4. Ali IU. Gatekeeper for the endometrium: the PTEN tumor suppressor gene. *J Natl Cancer Instit* 2000; 92(11):861-863.
5. Ali IU, Schriml LM, Dean M. Mutational spectra of the PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. *J Natl Cancer Instit* 1999; 91(22):1922-1932.
6. Ali-Fehmi R, Khalifeh I, Banyopadhyay S, Lawrence WD, Silva E, Liao D, Sarkar FH, Munkarah AR. Patterns of loss of heterozygosity at 10q23.3 and micro-satellite instability in endometriosis, atypical endometriosis and ovarian carcinoma arising in association with endometriosis. *Int J Gynecol Pathol* 2006; 25(3):223-229.
7. Amant F, De la Rey M, Dorfling C, Van der Walt L, Dreyer L, Dreyer G, Vergote I, Lindeque BG, Van Rensburg E. PTEN mutations in uterine sarcomas. *Gynecol Oncol* 2002; 85:165-169.
8. Amant F, Dorfling CM, De Brabanter J, Vandewalle J, Vergote I, Lindeque BG, Van Rensburg EJ. A possible role for the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. *Acta Obstet Gynecol Scand* 2004; 83:234-239.
9. Amant F, Dorfling C, Dreyer L, Vergote I, Lindeque BG, Van Rensburg E. Microsatellite instability in uterine sarcomas. *Int J Gynecol Cancer* 2001a; 11:218-223.
10. Amant F, Dreyer L, Makin J, Vergote I, Lindeque B. Uterine sarcomas in South African black women: a clinicopathological study with ethnic considerations. *Eur J Gynaecol Oncol* 2001b; 23:194-200.
11. Amant F, Vergote I. PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas. *Am J Obstet Gynecol* 2002; 187(1):258.
12. Ambros PF, Ambros IM, Strehl S, Bauer S, Luegmayr A, Kovar H, Ladenstein R, Fink FM, Horcher E, Printz G, et al. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? *Eur J Cancer*. 1995; 31A(4):510-515.

13. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. *Hum Pathol* 1995; 26(11):1260-1267.
14. An HJ, Kim KI, Kim JY, Shim JY, Kang H, Kim TH, Kim JK, Jeong JK, Lee SY, Kim SJ. Micro-satellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. *Am J Surg Pathol* 2007; 31:846-853.
15. An HJ, Logani S, Isacson C, Ellenson LH. Molecular characterization of uterine clear cell carcinoma. *Mod Pathol* 2004; 17:530-537.
16. Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, Gates EJ, Di Maio T, Marzec T. Uterine carcinosarcomas: incidence and trends in management and survival. *Gynecol Oncol* 1997; 65(1):158-163.
17. Aziz H, Rotman M, Hussain F, Smith G, Chan E, Choi K, Sohn C, Halpern J, Schwartz D, Aral I, et al. Poor survival in black patients in carcinoma of the endometrium. *Int J Radiat Oncol Biol Phys* 1993; 27(2):293-301.
18. Backman S, Stambolic V, Mak T. PTEN function in mammalian cell size regulation. *Curr Opin Neurobiol* 2002; 12(5): 516-522.
19. Bandera CA, Cramer DW, Friedman AJ, Sheets EE. Fertility therapy in the setting of a history of invasive epithelial ovarian cancer. *Gynecol Oncol* 1995; 58(1):166-119.
20. Bandera CA, Muto MG, Welch WR, Berkowitz RS, Mok SC. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. *Oncogene* 1998; 16(26):3455-3459.
21. Bandera CA, Takahashi H, Behbakht K, Liu PC, LiVolsi VA, Benjamin I, Morgan MA, King SA, Rubin SC, Boyd J. Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. *Cancer Res* 1997; 57(3):513-515.
22. Beckner et al 1985, Bell S, Kempson R, Hendrickson M. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213. *Am J Surg Pathol* 1994; 18:535-558.
23. Bell S, Kempson R, Hendrickson M. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. *Am J Surg Pathol* 1994; 18:535-558.
24. Bell DA. Origins and molecular pathology of ovarian cancer. *Mod Pathol* 2005;18(2):S19-32.
25. Berchuck A, Schildkraut JM, Wenham RM, Caligaert B, Ali S et al. Progesterone receptor promoter +331A polymorphism is associated with reduced risk of endometrioid and clear cell ovarian cancers. *Cancer Epidemiol Biomarker Prev* 2004; 13(12):2141-2147.
26. Berchuck A, Boyd J. Molecular basis of endometrial cancer. *Cancer* 1995; 76:2034-2040.

27. Berchuck A, Cirisano F, Lancaster JM, Scholdkraut JM, Wiseman RW, Futreal A, Marks JR. Role of BRCA1 mutation screening in the management of familial ovarian cancer. *Am J Obstet Gynecol* 1996; 175(3):738-746.
28. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC jr. Pathogenesis of ovarian cancers. *J Soc Gynecol Investig* 1994; 1(3):181-190.
29. Baiocchi G, Kavanagh JJ, Wharton JT. Endometrioid stromal sarcomas arising from ovarian and extraovarian endometriosis: report of two cases and review of the literature. *Gynecol Oncol* 1990; 36(1):147-151.
30. Bischoff FZ, Simpson JL. Heritability and molecular genetic studies of endometriosis. *Hum Reprod Update* 2000; 6(1):37-44.
31. Black D, Bogomolny L, Robson ME, Offit K, Barakat RR, Boyd J. Evaluation of germline mutations in endometrial cancer patients. *Gynecol Oncol* 2005; 96:21-24.
32. Blumenthal PD. Cervical cancer Prevention: Making programs more appropriate and pragmatic. *JAMA* 2005; 3(294):17.
33. Bokhman J. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol* 1983; 15:10-17.
34. Bonneau D, Longy M. Mutations in the human PTEN gene. *Hum Mutat* 2000; 16:109-122.
35. Bose S, Wang SI, Terry MB, Hibshoosh H, Parsons R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. *Oncogene* 1998; 17(1):123-127.
36. Boyd J. Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes. *Gynecol Oncol* 1996; 61(2):163-165.
37. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. *Gynecol Oncol* 1997; 64(2):196-206.
38. Boyd J. Molecular genetics of hereditary ovarian cancer. *Oncology* 1998; 12(3):399-413.
39. Boyd JA, Risinger JI. Analysis of oncogene alterations in human endometrial carcinoma: prevalence of *ras* mutations. *Molec Carcinogen* 1991; 4:189-4195.
40. Brinton LA, Gridley G, Persson I, Baron J & Bergqvist A 1997 Cancer risk after a hospital discharge diagnosis of endometriosis [Comment]. *Am J Obstet Gynecol* 1997; 176:572-579.
41. Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. *Histopath* 1998; 33:297-303.
42. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. *J Biol Chem* 2001; 276(13):9817-9824.
43. CANSA. 2002. http://www.cansa.co.za/registry_cervix.asp

44. Castiblanco GA, Pires NY, Wistuba OI, Riquelme SE, Andrade ML, Corvalan RA. [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis.] [Spanish] *Revista Med Chile* 2006; 134:271-278.
45. Catusus L, Bussaglia E, Rodriguez I, Gallardo A, Pons C et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-cadherin abnormalities but lower rate of micro-satellite instability and PTEN alterations than in uterine endometrioid carcinomas. *Hum Pathol* 2004; 35(11):1360-1368.
46. Catusus L, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas: clinicopathological correlations in a series of 42 cases. *Hum Pathol* 1998; 29:1160-1164.
47. Cerezo L, Cardenes H, Michael H. Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications. *Clin Translat Oncol* 2006; 8:231-241.
48. Chen Y, Zheng H, Yang X, Sun L, Xin Y. Effects of mutation and expression of PTEN gene mRNA on tumorigenesis and progression of epithelial ovarian cancer. *Chin Med Sciences J* 2004; 19:25-30.
49. Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. *Cancer Res* 1998; 58(11):2331-2334.
50. Zhang M, Yong Z, Binns CW, Lee AH. Diet and ovarian risk: a case-control study in China. *Am J Epidemiol* 1999; 149:21-31.
51. Chirara M, Stanczuk GA, Tswana SA, Nystrom L, Bergstrom S, Moyo SR, Nzara MJ. Low risk and high risk human papillomaviruses (HPVs) and cervical cancer in Zimbabwe: epidemiological evidence. *Centr Afr J Med* 2001; 47:32-35.
52. Cho MY, Kim HS, Eng C, Kim DS, Kang SJ, Eom M, Yi SY, Bronner MP. First report of ovarian dysgerminoma in Cowden syndrome with germline PTEN mutation and PTEN-related 10q loss of tumor heterozygosity. *Am J Surg Pathol* 2008; 32(8):1258-1264.
53. Choo Y. Recognition of DNA methylation by zinc fingers. *Nature Struct Biol* 1998; 5(4):264-265.
54. Christopherson W, Williamson E, Gray L. Leiomyosarcoma of the uterus. *Cancer* 1972; 29:1512-1517.
55. Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. *Mod Pathol* 2001; 14:465-471.
56. Cirpan T, Aygul S, Terek MC, Kazandi M, Dikmen Y, Zekioglu O, Sagol S. MMAC tumor suppressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. *Eur J Gynecol Oncol* 2007; 28:278-281.

57. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. *Nature* 1993; 362(6423):849-852.
58. Colgan TJ, Murphy J, Cole DE, Naros S, Rosen B. Occult carcinoma in prophylactically removed oophorectomy specimens: prevalence and association with BRCA germline mutation status. *Am J Surg Pathol* 2001; 25:1283-1289.
59. Connor P, Talavera F, Kang JS, Burke J, Roberts J, Menon KM. Epidermal growth factor activates protein kinase C in endometrial cancer cell line HEC-1-A. *Gynecol Oncol* 1997; 67:46-50.
60. Cox GS, Gutkin DW, Haas MJ, Cosgrove DE. Isolation of an Alu repetitive DNA binding protein and effect of CpG methylation on binding to its recognition sequence. *Biochem Biophys Acta* 1998; 1396(1): 67-87.
61. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. *Cell* 2002; 110(6):737-749.
62. Crowder RJ, Lombardi DP, Ellis MJ. Successful targeting of ErbB2 receptors– is PTEN the key? *Cancer Cell* 2004; 6:103-104.
63. Dahia PLM, Aguiar RCT, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C, Eng C. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. *Hum Mol Genet* 1999; 8(2):185-193.
64. Dahia PLM, Fitzgerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, Von Deimling A, Haluska FG, Haber DA, Eng C. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. *Oncogene* 1998; 16:2403-2406.
65. Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, Soslow RA. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. *Am J Surg Pathol* 2004; 28:1568-1578.
66. Darwish AN, Makhlof AM, Youssof AA, Gadalla HA. Hysteroscopic myometrial biopsy in unexplained abnormal uterine bleeding. *Eur J Obstet Gynecol Reprod Biol* 1999; 86(2):139-143.
67. Davies MA, Koul D, Dhese H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. *Cancer Res* 1999; 59(11):2551-2556.
68. Davies MP, Gibbs FE, Halliwell N, Joyce KA, Roebuck MM, Rossi ML, Salisbury J, Sibson DR, Tacconi L, Walker C. Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. *Br J Cancer* 1999; 79(9-10):1542-1548.
69. De Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, De Bock GH, De Vries EG, De Jong S, Van der

- Zee AG. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. *Br J Cancer* 2008; 99:341-349.
70. Deguchi M, Matsumoto Y, Ishiko O, Oghita S. Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis. *Oncol Rep* 2000; 7(3):651-654.
 71. Del Carmen MG, Smith-Sehdev AE, Fader AN, Zahurak ML, Richardson M et al. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. *Cancer* 2003; 98(8):1658-1659.
 72. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. *Cancer* 1985; 56(6):1452-1455.
 73. Diebold J. [Phenotype-genotype correlation in ovarian neoplasia.] [German] *Verh Dtsch Ges Pathol* 2001; 85:153-160.
 74. Diebold J. [Molecular carcinogenesis of ovarian carcinoma.] [German] *Verh Dtsch Ges Pathol* 2005; 89:77-83.
 75. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. *Nat Med* 2005; 11(1):63-70.
 76. Dixon JE. Bacterial and viral protein tyrosine phosphatases. *J Biol Chem* 1999; 274:14053-14061.
 77. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colas E, Llauro M, Alazzouzi H, Planaguma J, Lohmann MA, Garcia J, et al. Novel molecular profiles of endometrial cancer – new light through old windows. *J Ster Biochem Molec Biol* 2008; 108:221-229.
 78. Donnez J, Spada F, Squifflet J, Nisolle M. Bladder endometriosis must be considered as bladder adenomyosis. *Fertil Steril* 2000; 74(6):1175-1181.
 79. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. *Curr Opin Cell Biol* 1998; 10:262-267.
 80. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. *Science* 1997; 275(5300):661-665.
 81. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, Von Deimling A. PTEN mutations in gliomas and glioneuronal tumors. *Oncogene* 1998; 16(17):2259-2264.
 82. Duggan BD, Felix JC, Muderspach LI, Tsao JL, Shibata DK. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. *Cancer Res* 1994; 54:1604-1607.
 83. Durst M, Gissman L, Ikenberg H, Zur Hausen H. A new papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. *Proc Natl Acad Sci USA*. 1983; 80:3812-3815.

84. Enomoto T, Fujita M, Fujita M. Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. *Br J Cancer* 1995; 71:462-467.
85. Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O, Rice JM. K-ras activation in neoplasms of the human female reproductive tract. *Cancer Res* 1990; 50:6139-6145.
86. Erzen M, Rakar S, Klancnik B, Syrjanen K. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. *Gynecol Oncol* 2001; 83(1):100-108.
87. Evans HL, Chawla SP, Simpson C, Finn KP. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. *Cancer* 1988; 62:2239-2247.
88. Fauman EB, Saper MA. Structure and function of the protein tyrosine phosphatases. *Trends Biochem Science* 1996; 21:413-417.
89. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990; 61:759-767.
90. Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboue B, Latham WCW, Eng C, Mulligan LM, Longy M. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. *Br J Cancer* 1999; 79(5/6):718-723.
91. Ferenczy A. Pathophysiology of adenomyosis. *Human Reproduction Update*. 1998; 4(4): 312-322.
92. Fisher SG. Epidemiology: a tool for the study of human papillomavirus-related carcinogenesis. *Intervirolgy* 1994; 37:215-225.
93. Fishman A, Demirel D, Laucirica R, Ramsy I, Klima T. Malignant tumors arising in endometriosis: clinical-pathological study and flow-cytometry analysis. *Eur J Obstet Gynecol Reprod Biol* 1996; 70(1):69-74.
94. Fotiou SK, Tserkezoglou AJ, Mahera H, Konstandinidou AE, Agnantis NJ, Pandis N, Bardi G. Chromosome aberrations and expression of ras and myc oncogenes in leiomyomas and a leiomyosarcoma of the uterus. *Eur J Gynaecol Oncol* 1992; 13(4):340-345.
95. Frazer IH et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. *Pediatr Infect Dis J* 2006; 25:S65-S81.
96. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Drya TP. A human DNA segment with propoerties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 1986; 323: 643-646.
97. Fujii H, Yoshida, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, Hruban RH, Gabrielson E, Shirai T. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. *Cancer Res* 2000; 60(1):114-120.

98. Fujii GH, Morimoto AM, Berson AE, Bolen JB. Transcriptional analysis of the PTEN/MMAC1 pseudogene, Ψ PTEN. *Oncogene* 1999; 18:1765-1769.
99. Fujii H, Matsumoto T, Yoshida M, Furugen Y, Takagaki T, Iwabuchi K, Nakata Y, Takagi Y, Moriya T, et al. Genetics of synchronous uterine and ovarian endometroid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and micro-satellite instability. *Hum Pathol* 2002; 33(4):421-428.
100. Fujimoto J, Sakaguchi H, Hirose R, Wen H, Tamaya T. Angiogenesis in endometriosis and angiogenic factors. *Gynecol Obstet Invest* 1999; 48(S1):14-20.
101. Fujimoto I, Shimizu Y, Hirai Y, Chen T, Teshima H, Hasumi K, Masubuchi K, Takahashi M. Studies on Ras oncogene activation in endometrial carcinoma. *Gynecol Oncol* 1993; 48:196-202.
102. Fukunaga M, Ishihara A, Ushigome S. Extrauterine low-grade endometrial stromal sarcom: a report of three cases. *Pathol Int* 1998; 48(4):297-302.
103. Fukunaga M. Smooth muscle metaplasia in ovarian endometriosis. *Histopathology* 2000; 36(4):348-352.
104. Fults D, Pedone CA, Thomas GA, White R. Allelotype of human malignant astrocytoma. *Cancer Res* 1990; 50:5784-5789.
105. Furnari FB, Huang SHJ, Cavaneer WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. *Cancer Res* 1998; 58:5002-5008
106. Furnari FB, Lin H, Huang HS, Cavaneer WK. Growth suppression of glioma cells by PTEN requires a functional phosphates catalytic domain. *Proc Natl Acad Sci* 1997; 94(23):12479-12484.
107. Gaducci A, Tana R, Cosio S, Fanucchi A, Genazzani AR. Molecular target therapies in endometrial cancer: from basic research to the clinic. *Gynecol Endocrinol* 2008; 24:239-249.
108. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. *Gynecol Oncol* 1999; 75(3):432-436.
109. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. *Gynecol Oncol* 1998; 71:305-307.
110. Gilmore AP, Romer LH. Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. *Mol Biol Cell* 1996; 7:1209-1224.
111. Gima T, Kato H, Honda T, Imamura T, Sasazuki T, Wake N. DCC gene alteration in human endometrial carcinomas. *Int J Cancer* 1994; 57:480-485.

112. Gokaslan H, Turkeri L, Kavak ZN, Eren F, Sismanoglu A, Ilvan S, Durmusoglu F. Diggerential diagnosis of smooth muscle tumors utilizing p53, PTEN and Ki-67 expression with estrogen and progesterone receptors. *Gynecol Obstet Investig* 2005; 59:36-40.
113. Goldie SJ et al. Cost-effectiveness of cervical-cancer screening in five developing countries. *N Engl J Med*. 2005; 353:2158-2168.
114. Gomes CP, Andrade LA. PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms. *Int J Gynecol Cancer* 2006; 16(suppl 1):254-258.
115. Gorai I, Yanagibashi T, Taki A, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Nagashima Y, Minaguchi H. Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. *Int J Cancer* 1997; 72(5):821-827.
116. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK. Loss of the chromosomal region 10q23-25 in prostate cancer. *Cancer Res* 1995; 55:4800-4803.
117. Grucer F, Reich O, Tamussino K, Bader AA, Scholl W, Haas J, Petru E. Concomitant endometrial hyperplasia in patients with endometrial carcinoma. *Gynecol Oncol* 1998; 69(1):64-68.
118. Gu J, Tamura M, Yamada KM. Tumour suppressor PTEN inhibits integrin- and growth factor-mediated MAP kinase signalling pathways. *J Cell Biol* 1998; 143:1375-1383.
119. Guarch R, Puras A, Ceres R, Isaac MA, Nogales FF. Ovarian endometriosis and clear cell carcinoma, leiomyomatosis peritonealis disseminate and endometrial adenocarcinoma: an unusual pathogenetically related association. *Int J Gynecol Pathol* 2001; 20(3):267-270.
120. Guarino M, Giordano F, Pallotti F, Polizzotti G, Tricomi P, Christofori E. Malignant mixed mullerian tumor of the uterus. Features favoring its origin from a common cell clone and an epithelial-to-mesenchymal transformation mechanism of histogenesis. *Tumori* 1998; 84(3):391-397.
121. Guldberg P, Straten PT, Birck A, Ahrenkiel V, Kirken AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. *Cancer Res* 1997; 57:3660-3663.
122. Gunter Kieback D, Fischer DC. Gene expression profile in endometrioid endometrial carcinoma. *Gynecol Oncol* 2001; 83(2):175-176.
123. Guo L, Liu T, Lang J. The malignant potential of ovarian atypical endometriosis. *Chin J Pathol* 2001; 30(3):169-172.
124. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinomas. *Cancer Res* 1999; 59(2):462-466.
125. Hansen G, Oren NN. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains. *Oncogene* 1999; 18(14):2405-2410.

126. Harlow B, Weiss N, Lofton S. The epidemiology of sarcomas of the uterus. *J Natl Cancer Inst* 1986; 76:399-402.
127. Harris H, Miller OJ, Kein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. *Nature* 1969; 223:363-368.
128. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC. PTEN expression in clear cell adenocarcinoma of the ovary. *Gynecol Oncol* 2006; 101:71-75.
129. Healy DL, Burmeister L. Ovarian cancer in infertility patients. *Ann Med* 1998; 30(6):525-528.
130. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. *Obstet Gynecol* 1990; 75(6):1023-1028.
131. Hirai M, Hirono M, Oosaki T, Hayashi Y, Yoshihara T, Matsuzaki O. Prognostic factors relating to survival in uterine endometrioid carcinoma. *Int J Gynaecol Obstet* 1999; 66(2):155-162.
132. Ho CM, Lin MC, Huang SH, Huang CJ, Lai HC, Chien TY, Chang SF. Pten promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell carcinomas. *Gynecol Oncol* 2009; 112:307-313.
133. Hopkins K. A surprising function for the PTEN tumour suppressor. *Science* 1998; 282:1027-1030.
134. Huang J, Kontos CD. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. *J Biol Chem* 2002; 277(13):10760-10766.
135. Huang S. Gene expression profiling, genetic networks, and cellular states: an integrating concept for tumorigenesis and drug discovery. *J Mol Med* 1999; 77:469-480.
136. Huang Y, Peng J, Oberley LW, Domann FE. Transcriptional inhibition of manganese superoxide dismutase (SOD2) gene expression by DNA methylation of the 5' CpG island. *Free Radical Biol Med* 1997; 23(2):314-320.
137. Hunter T. The Croonian lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. *Philos Trans R Soc Lond B Biol Sci* 1998; 353:583-605.
138. Ioffe OB, Papadimitiou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic and malignant endometrium. *Hum Pathol* 1998; 29:1150-1159.
139. Ionov Y, Peinado MA, Malkhoysyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveals a new mechanism for colonic carcinogenesis. *Nature* 1993; 363:558-561.
140. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, Silverberg SG, Garrett CT. Prognostic significance of p53 overexpression in endometrial cancer. *Cancer Res* 1994; 54(17):4667-4670.

141. Jacobs I, Lancaster J. The molecular genetics of sporadic and familial epithelial ovarian cancer. *Int J Gynecol Cancer* 1996; 6:337-355.
142. Jamison JCA. The role of PTEN gene mutations in hyperplasia and carcinoma of the endometrium. 2004. University of Pretoria (unpublished dissertation).
143. Jang KH, Chambers PJ, Britz ML. Analysis of nucleotide methylation in DNA from *Corynebacterium glutamicum* and related species. *FEMS Microbiol Letters*. 1996; 136(3):309-315.
144. Jin X, Gossett DR, Wang S, Yang D, Cao Y, Chen J, Guo R, Reynolds RK, Lin J. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. *Br J Cancer* 2004; 91:1808-1812.
145. Jongsma AP, Piek JM, Zweemer RP, Verheijen RH, Klein Gebbinck JW, Van Kamp GJ, Jacobs IJ, Shaw P, Van Diest PJ, Kenemans P. Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. *Mol Pathol* 2002; 55(5):305-309.
146. Kahanpaa K, Wahlstrom T, Grohn P, Heinonen E, Nieminen U, Widholm O. Sarcomas of the uterus: a clinicopathological study of 119 patients. *Obstet Gynecol* 1986; 67:417-424.
147. Kaku T, Kamura T, Hirakawa T, Sakai K, Amada S, Kobayashi H. Endometrial carcinoma associated with hyperplasia - immunohistochemical study of angiogenesis and p53 expression. *Gynecol Oncol* 1999; 72(1):51-55.
148. Kanaya T, Kyo S, Sakaguchi J, Maida Y, Nakamura M, Takakura M, Hashimoto M, Mizomoto Y, Inoue M. Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and its precursors in a Japanese population. *Am J Clin Pathol* 2005; 124:89-96.
149. Kavanagh JJ, Wharton JT. Endometrioid stromal sarcomas arising from ovarian and extraovarian endometriosis: report of two cases and review of the literature. *Gynecol Oncol* 1990; 36(1):147-151.
150. Kay PH, Spagnolo DV, Taylor J, Ziman M. DNA methylation and developmental genes in lymphomagenesis – more questions than answers? *Leukemia Lymphoma* 1997;24(3-4): 211-220.
151. Kayisli UA, Berkanoglu M, Kizilay G, Senturk L, Arici A. Expression of proliferative and preapoptotic molecules in human myometrium and leiomyoma throughout the menstrual cycle. *Reprod Sciences* 2007; 14:678-686.
152. Kennedy SG, Wagner AJ, Conzen SD, Jordán J, Bellacosa A, Tsihchlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. *Genes Dev* 1997; 11(6):701-713
153. Khalifa MA, Mannel R, Haraway S, Walker J, Min K. Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. *Gynecol Oncol* 1994; 53:84-92.

154. Khan JA et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. *J Adol Health* 2005; 37:502-510.
155. Kiebach DG, Fischer DC. Gene expression profile in endometrioid endometrial carcinoma. *Gynecol Oncol* 2001; 83:175-176.
156. Kiechle-Schwartz M, Berger CS, Surti U, Sandberg AA Rearrangement of band 10q22 in leiomyoma and leiomyosarcoma of the uterus. *Cancer Genet Cytogenet* 1990; 47:95-100.
157. Kimura F, Watanabe J, Hata H, Fujisawa T, Kamata Y, Nishimura Y, Jobo T, Kuramoto H. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. *J Cancer Res Clin Oncol* 2004; 130 161-168.
158. Kimura T, Azuma C, Saji F, Tokugawa Y, Takemura M, Miki M, Ono M, Tanizawa O. The biological effects of macrophage colony stimulating factor induced by progestin on growth and differentiation of endometrial adenocarcinoma cells. *Int J Cancer* 1991; 49:229-233.
159. Kleymenova EV, Yuan X, LaBate ME, Walker CL. Identification of a tumor-specific methylation site in the Wilms tumor suppressor gene. *Oncogene* 1998; 16(6):713-720.
160. Knudson AG. Genetic predisposition to cancer. *Cancer Detect Prev* 1984; 7(1):1-8.
161. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci* 1971; 68:820-823.
162. Kobayashi H. Invasive capacity of heterotopic endometrium. *Gynecol Obstet Invest* 2000; 50 (1):26-32.
163. Koffa M, Spandidos DA. Oncogenes and onco-suppressor genes in female genital cancer. *Ann New York Acad Sci* 1997; 816:347-355.
164. Köhler T, Heinisch M, Kirchner M, Peinhardt G, Hirschelmann R, Nuhn P. Phospholipase A2 inhibition by alkylbenzoylacrylic acids. *Biochem Pharmacol* 1992; 44(4):805-813.
165. Kolasa IK, Rembiszewska A, Janiec-jankowska A, Dansonka Mieszkowska A, Lewandowska AM, Konopka B, Kupryjanczyk J. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. *Gynecol Oncol* 2006; 103:692-697.
166. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp L, Wakatsuki S, Yokohama T, Yamakawa H, Furukawa T, et al. PTEN is frequently mutated in primary endometrial carcinomas. *Nat Genet* 1997; 17:143-144.
167. Konishi H, Matsuzaki H, Tanaka M, Ono Y, Tokunaga C, Kuroda S, Kikkawa U. Activation of RAC-protein kinase by heat shock and hyperosmolarity stress through a pathway independent of phosphatidylinositol 3-kinase. *Proc Natl Acad Sci USA* 1996; 93(15):7639-7643.

168. Konopka B, Janiec-Janowska A, Paszko Z, Goluda M. The co-existence of ErbB2, Int2, and C-myc oncogene amplifications and PTEN gene mutations in endometrial carcinoma. *J Cancer Res Clin Oncol* 2004; 130:114-121.
169. Konopka B, Paszko Z, Janiec-Janowska A, Goluda M. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. *Cancer Lett* 2002; 178(1):43-51.
170. Koul A, Borg A, Pejovic T, Bendahl PO, Högberg T, Iosif CS, Killander D. Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. *Gynecol Oncol* 1997; 67(3):295-302.
171. Kovac D, Gasparovic I, Jasic M, Fuckar D, Dobi-Babic R, Haller H. Endometrial stromal sarcoma arising in extrauterine endometriosis: a case report. *Europ J Gynaecol Oncol* 2005; 26(1):113-116.
172. Kovacs KA, Lengyel F, Vertes Z, Kornyei JL, Gocze PM, Sumegi B, Szabo I, Vertes M. Phosphorylation of PTEN protein is enhanced in human fibromyomatous uteri. *J Ster Biochem Molec Biol* 2007; 103:196-199.
173. Kovalev S, Marchenko ND, Gugliotta BG, Chalas E, Chumas J, Moll UM. Loss of p53 functions in uterine papillary serous carcinoma. *Hum Pathol* 1998; 29(6):613-619.
174. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. *Mol Cell Biol* 1997; 17(3):1595-1606.
175. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. *JAMA* 1994; 271(23):1866-1869.
176. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. *Am J Pathol* 2001; 158(6):2097-2106.
177. Kurose K, Bando K, Fukino K, Sugisaki Y, Araki T, Emi M. Somatic mutations of the PTEN/MMAC1 gene in fifteen Japanese endometrial cancers: evidence for inactivation of both alleles. *Jpn J Cancer Res* 1998; 89:842-848.
178. Kusuki I, Kitawaki J, Ishihara H, Koshiba H, Kado N, Ohshima K, Honjo H. Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2001; 98(1):114-118.
179. Kwon YS, Nam JH, Choi G. Clear cell adenocarcinoma arising in endometriosis of a previous episiotomy site. *Obstet Gynecol* 2008; 112(2 Pt 2):475-477.
180. Lacey CJN. Therapy for genital human papillomavirus-related disease. *J Clin Virol* 2005; 32S:S82-S90.
181. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. *Hum Pathol* 1988; 19(9):1080-1084.

182. Lancaster JM, Risinger JI, Carney ME, Barret JC, Berchuck A. Mutational analysis of the PTEN gene in human uterine sarcomas. *Am J Obstet Gynecol* 2001; 184(6):1051-1053.
183. Latta E, Chapman WB. PTEN mutations and evolving concepts in endometrial neoplasia. *Curr Opin Obstet Gynecol* 2002; 14(1):59-65.
184. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. *Cancer* 2000; 88(4):814-824.
185. Laxman R, Currie J, Kurman R, Dudzinski M, Griffin C. Cytogenetic profile of uterine sarcomas. *Cancer* 1993; 71:1283-1288.
186. Lee JS, Choi YD, Choi C, Park CS, Min KW. Expression of PTEN in ovarian epithelial tumours and its relation to tumour behaviour and growth. *Analyt Quantit Cytol Histol* 2005; 27:202-210.
187. Lee KR, Nucci MR. Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathological analysis of four cases of an uncommon variant associated with endometriosis. *Int J Gynecol Pathol* 2003; 22(1):42-51.
188. Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, Blick M. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. *Cancer Res* 1990; 50(9):2724-2728.
189. Leiserowitz GS, Harris SA, Subramaniam M, Keeney GL, Podratz KC, Spelsberg TC. The proto-oncogene c-fms is overexpressed in endometrial cancer. *Gynecol Oncol* 1993; 49(2):190-6.
190. Leiserowitz GS, Gumps JL, Dalrymple JL, Smith LH, et al. Endometriosis-related malignancies. *Int J Gynecol Cancer* 2003; 13(4):466-471.
191. Levenback CF, Tortolero-Luna G, Pandey DK, Malpica A, Baker VV, Whittaker L, Johnson E, Mitchell MF. Uterine sarcoma. *Obstet Gynecol Clin N Am* 1996; 23(2):457-473.
192. Levгур M, Abadi MA, Tucker A. Adenomyosis: symptoms, histology, and pregnancy terminations. *Obstet Gynecol* 2000; 95(5):688-691.
193. Levine RL, Cargile CB, Blazes MS, Van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia. *Cancer Res* 1998; 58(15):3254-3258.
194. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. *Proc Natl Acad Sc* 1998a; 95:15406-15411.
195. Li DM, Sun H. TEP1, encoded by a candidate tumour suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. *Cancer Res* 1997a; 57(11):2124-9.

196. Li J, Simpson L, Takahashi M, Myers MP, Tonks N, Parsons R. The PTEN/MMAC1 tumour suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. *Cancer Res* 1998b; 58(24):5667-5672.
197. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 1997b; 275(5308):1943-1947.
198. Li L, Liu F, Salmonsens RA, Turner TK, Litofsky NS, Christofano A, Pandolfi PP, Jones SN, Recht LD, Ross AH. PTEN in neuronal precursor cells: regulation of migration, apoptosis and proliferation. *Molec Cell Neurosciences* 2002; 20(1):21-29.
199. Li P, Nicosia SV, Bai W. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. *J Biol Chem* 2001; 276(23):20444-20450.
200. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* 1997; 16(1):64-67.
201. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH. Valproic acid resensitizes cisplatin resistant ovarian cancer cells. *Cancer Science* 2008; 99: 1218-1226.
202. Lin J, Sun C, Li R. Gonadotropin releasing hormone agonists in the treatment of adenomyosis with infertility. *Chung Hua Fu Chan Ko Tsa Chih* 1999; 34(4):214-216.
203. Lin WM, Forgacs E, Warshal DP, Yeh IT, Martin JS, Ashfaq R, Muller CY. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. *Nature* 1998;4(11):2577-2583
204. Liu JR, Conaway M, Rodriguez GC, Soper JT, Clarke-Pearson DL, Berchuck A. Relationship between race and interval treatment in endometrial cancer. *Obstet Gynecol* 1995; 86(4):486-490.
205. Liu FS, Kohler M, Marks J, Bast R, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. *Obstet Gynecol* 1994; 83:118-124.
206. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC (jr), Berchuck A. Multivariable analysis of DNA ploidy, p53 and HER-2/neu as prognostic factors in endometrial cancer. *Cancer* 1994; 73:2380-2385.
207. Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. *Obstet Gynecol* 1991; 78(1):63-9.
208. Lurain JR. Familial ovarian cancer. *JAMA* 1991; 266(23):3343.
209. Lurain JR. The significance of positive peritoneal cytology in endometrial cancer. *Gynecol Oncol* 1992; 46(2):143-144.
210. Lurain J. Cancer of the ovary. *N Engl J Med* 1994; 330(14):1012-1013.

211. Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji TT, Dann J, Swisshelm K, Suchard D, MacLeod PM, et al. Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. *Am J Hum Genet* 1997; 61(6):1254-1260.
212. Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, et al. The activity of lletrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical trials Group. *Int J Gynecol Cancer* 2004; 14(4):650-658.
213. Macwhinnie N, Monaghan H. The use of p53, PTEN and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. *Int J Gynecol Cancer* 2004; 14:938-946.
214. Madison T, Schottenfeld D, Baker V. Cancer of the corpus uteri in white and black women in Michigan, 1985-1994: An analysis of trends in incidence and mortality and their relation to histologic subtype and stage. *Cancer* 1998; 83(8):1546-1554.
215. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* 1998; 273(22):133725-133728.
216. Maia H (jr), Mltez A, Athayde C, Coelho G, Coutinho E. Detection of endometrial intraepithelial neoplasia (EIN) in postmenopausal endometrium. *Maturitas* 2003; 46:153-161.
217. Major F, Blessing J, Silverberg S, Morrow C, Creasman W, Currie, J, Yordan E, Brady M. Prognostic factors in early stage uterine sarcoma. A Gynecologic Oncology Group study. *Cancer* 1993; 71:1702-1709.
218. Malmstrom H, Blom R, Guerrieri C. Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases. *Int J Gynecol Cancer* 1999; 9(2):98-104.
219. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboue B, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutations. *Hum Molec Genet* 1998; 7(3):507-515.
220. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. Germline mutations in PTEN are present in patients with Bannayan-Zonana syndrome. *Nat Genet* 1997; 16:333-334.
221. Martini M, Ciccarone M, Garganese G, Maggiore C, Evangelista A et al. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. *Int J Cancer* 2002; 102(4):398-406.
222. Matias-Guiu X, Catusus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Argielles R, Machin P, Prat J. Molecular pathology of endometrial hyperplasia and carcinoma. *Human Pathol* 2001; 32: 569-577.
223. Maxwell GL, Carlson JW. Oncogenes in gynecologic oncology. *Obstet Gynecol Surv* 1996; 51(12):710-717.

224. Maxwell G, Risinger J, Hayes K, Alvarez A, Dodge R, Barrett J, Berchuck A. Racial disparity in the frequency of PTEN mutations but not microsatellite instability in advanced endometrial cancers. *Clin Cancer Res* 2000; 6:2999-3005.
225. Maxwell GL, Carlson JW. Oncogenes in Gynecological Oncology. *Obstet Gynecol Survey* 1996; 51:710-717.
226. Maxwell GL, Chandramouli VR, Dainty L, Litzi T, Bidus MA et al. Racial disparity in global gene expression among patients with advanced endometrial adenocarcinoma. *Gynecol Oncol* 2005; 96:922-1020.
227. Maxwell GL, Risinger JI, Gumps C, Shaw H, Bentley RC, Barrett JC, Berchuck A, Futreal P. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. *Cancer Res* 1998a; 58:2500-2503.
228. Maxwell GL, Risinger JI, Tong B, Shaw H, Barrett JC, Berchuck A, Futreal P. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. *Gynecol Oncol* 1998b; 70:13-16.
229. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. *J Biol Chem* 2001; 277:5484-5489.
230. McCampbell AS, Broaddus RR, Loose DS, Davies PJ. Overexpression of the insulin-like growth factor 1 receptor and activation of the AKT pathway in hyperplastic endometrium. Comment in: *Clin Cancer Res* 2006; 12:6323-6325.
231. McCluggage W, Abdulkader M, Price J, Kelehan P, Hamilton S, Beattie J, Al-Nafussi A. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. *Int J Gynecol Pathol* 2000; 10:280-284.
232. Mhawech M, Kinkel K, Vlastos G, Pelte MF. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study. *Int J Gynecol Pathol* 2002; 21(4):401-406.
233. Mills GB, Lu Y, Fang X, Wang H, Eder A et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis and therapy. *Semin Oncol* 2001; 28(5S16):125-141.
234. Minaguchi T, Yoshikawa K, Oda K, Ishino T, Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K, Taketani Y. PTEN mutation located only outside exons 5,6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. *Clin Cancer Res* 2001; 7(9):2636-2642.
235. Mizumoto Y, Kyo S, Ohno S, Hashimoto M, Nakamura M, Maida Y, Sakaguchi J, Takakura M, Inoue M, Kiyono T. Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements. *Oncogene* 2006; 25:5673-5682.
236. Mizuuchi H, Nasim S, Kudo R, Silverberg G, Greenhouse S, Garret CT. Clinical implications of K-ras mutations in malignant epithelial tumours of the endometrium. *Cancer Res* 1992; 52:2777-2781.

237. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian and extraovarian endometriosis-associated cancer. *Obstet Gynecol* 2002; 100:788–795.
238. Moinfar F, Kremser ML, Man YG, Zatloukal K, Tavassoli FA, Denk H. Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues. *Gynecol Oncol* 2004; 95(3):662-671.
239. Monk BJ, Chapman JA, Johnson G, Brightman B, Wilczynski S, Schell MJ, et al. Correlation of c-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. *Am J Obstet Gynecol* 1994; 171:1193-1198.
240. Morsi HM, Leers MP, Radespiel-Troger M, Bjorklund V, Kabarity HE, Nap M, Jager W. Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: An approach using multiparameter flow cytometry. *Gynecol Oncol* 2000; 77:11-17.
241. Munoz N et al. Against which human papillomavirus types shall we vaccinate & screen. The international perspective. *Int J Cancer* 2004; 111:278-285.
242. Munoz N et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med* 2003; 348:518-527.
243. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Hum Mol Genet* 1998; 7(3):507-515.
244. Muto MG, Welch WR, Mok SC, Bandera CA, Fishbaugh PM, Tsoa SW, Lau CC, Goodman HM, Knapp RC, Berkowitz RS. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. *Cancer Res* 1995; 55(3):490-492.
245. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JPA, Lees JA, Weng LP, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial pre-cancers. *J Natl Cancer Instit* 2000; 92(11): 924-930.
246. Mutter GL, Waqda H, Faquin WC, Enomoto T. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. *Mol Pathol* 1999; 124:257-262
247. Muthupei MN, Maluleke HJ. Malignant mixed mullerian tumours of the body of the uterus: a clinicopathological study of 20 cases. *Centr Afr J Med* 1998; 44(2):45-47.
248. Myers MP, Stolarov JP, Eng C, Li, J, Wang S, Wigler M, Parsons R, Tonks NK. P-TEN, the tumour suppressor from human chromosome 10q23, is a dual-specificity phosphatase. *Proc Natl Acad Sci USA* 1997a; 94:9052-9057.
249. Myers MP, Tonks NK. PTEN: Sometimes taking it off can be better than putting it on. *Am J Hum Genet* 1997; 61:1234-1238.
250. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. The lipid phosphatase activity of PTEN

- is critical for its tumor suppressor function. *Proc Natl Acad Sci USA* 1998; 95(23):13513-13518.
251. Nagase S, Sato S, Tezuka F, Wada Y, Yajima A, Horii A. Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. *Br J Cancer* 1996; 74(12):1979-1983.
 252. Nagase S, Yamakawa H, Sato S, Yajima A, Horii A. Identification of a 790-kilobase region of common allelic loss in chromosome 10q25-q26 in human endometrial cancer. *Cancer Res* 1997; 57(9):1630-1633.
 253. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, et al. PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell* 2004; 6:117-127.
 254. Nakahara Y, Nagai H, Kinoshita T, Uchida T, Hatano S, Murate T, Saito H. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. *Leukemia* 1998; 12(8):1277-1280.
 255. Nakayama K, Toki T, Nikaido T, Zhai YL, Konishi I. Genetic alterations in microsatellite marker sites among tumor suppressor genes in endometriosis. *Gynecol Obstet Invest* 2001; 51(4):240-242.
 256. Nelen M, Van Staveren WCG, Peeters EAJ, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons R, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. *Hum Molec Genet* 1997; 6:1383-1387.
 257. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. *J Natl Cancer Instit* 2000; 92(2):162-163.
 258. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. *Am J Epidemiol* 2002; 155(3):217-224.
 259. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. *Am J Obstet Gynecol* 2003; 189(1):280-294.
 260. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Berber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. *Am J Hum Genet* 1998; 62(2):1381-1388.
 261. Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. *Cancer* 2002; 94(11):2935-2940.
 262. Niederacher D, An HX, Cho YL, Hantschmann P, Bender HG, Beckmann MW. Mutations and amplification of oncogenes in endometrial cancer. *Oncology* 1999; 56:59-65.
 263. Niemann TH, Yilma AG, McGaughy VR, Vaccarello L. Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. *Gynecol Oncol* 1997; 65(2):232-236.

264. Ninaguchi T, Mori T, Kanamori Y, Yoshikawa H, Takentani Y et al. Growth suppression of ovarian cancer cells by adenovirus mediated transfer of the PTEN gene. *Cancer Res* 1999; 59(24):6063-6067.
265. Nishida M, Watanabe K, Satop N, Ichikawa Y. Malignant transformation of ovarian endometriosis. *Gynecol Obstet Invest* 2000; 50(S1):18-25.
266. Niwa K, Itoh M, Murase T, Morishita S, Itoh N et al. Alteration of the p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. *Br J Cancer* 1994; 70(6):1191-1197.
267. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. *Eur J Cancer* 1997; 33(6):907-911.
268. Obata K, Hoshiaia H. Common genetic changes between endometriosis and ovarian cancer. *Gynecol Obstet Invest* 2000; 50(S1):39-43.
269. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG. Frequent PTEN/MMAC mutations in endometroid but not serous or mucinous epithelial ovarian tumors. *Cancer Res* 1998; 58(10):2095-2097.
270. Ogawa K, Sun C, Horii A. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3/AKT cascade. *Oncol Reports* 2005; 14(6):1481-1485.
271. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. *Gynecol Oncol* 2000; 77:298-304.
272. Okuda T, Otsuka J, Sekizawa A, Saito H, Makino R et al. P53 mutations and overexpression affect prognosis of ovarian endometroid cancer but not clear cell cancer. *Gynecol Oncol* 2003; 88(3):318-325.
273. Oliva E, Sarrio D, Brachtel EF, Sanchez-Estevéz C, Soslow RA, Moreno-bueno G, Palacios J. High frequency of beta-catenin mutations in borderline endometroid tumours fo the ovary. *J Pathol* 2006; 208:708-713.
274. 1. Olivier RI, Van Beurden M, Lubsen MA, Rookus MA, Mooij TM, va de Vijver MJ et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. *Br J Cancer* 2004; 90:1492-1497.
275. Olschwang S, Serova-Sinilnikova OM, Lenoir GM, Thomas G. PTEN germ-line mutations in juvenile polyposis coli. *Nat Genet* 1998; 18:12-14.
276. Orbo A, Kaino T, Arnes M, Kopp M, Eklo K. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development. *Gynecol Oncol* 2004; 95:82-88.
277. Ota H, Igarashi S, Tanaka T. Xanthine oxidase in eutopic and ectopic endometrium in endometriosis and adenomyosis. *Fertil Steril* 2001; 75(4):785-790.
278. Ota H, Igarashi S, Hatazawa J, Tanaka T. Is adenomyosis an immune disease? *Human Reprod Update* 1998; 4(4):360-367.

279. Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T, Kushima M, Tachikawa T. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. *Med Electron Microsc* 2004; 37(3):188-192.
280. Otsuka M, Tsuchiya S, Aramaki Y. Involvement of ERK, a MAP kinase, in the production of TGF-beta by macrophages treated with liposomes composed of phosphatidylserine. *Biochem Biophys Res Commun* 2004; 324(4):1400-1405.
281. Ozaki T, Takahashi K, Okada M, Kurioka H, Miyazaki K. Live birth after conservative surgery for severe adenomyosis following magnetic resonance imaging and gonadotropin-releasing hormone agonist therapy. *Int J Fertil Womens Med* 1999; 44(5):260-264.
282. Packenham JP, Du Manoir S, Schrock R, Risinger JI, Dixon D, Denz DN, Evans JA, Berchuck A, Barrett JC, Devereux TR, Ried T. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. *Mol Carcinogen* 1997; 19(4):273-279.
283. Pafumi C, Farina M, Pernicone G, Russo A, Bandiera S, Giardina P, Cianci A. Adenomyosis and uterus rupture during labor. *Chung Hua I Hsueh Tsa Chih (Taipei)*. 2001; 64(4):244-246.
284. Pagliuisi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. *Vaccine* 2004; 23:569-578.
285. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. *Gynecol Oncol* 2001; 80:176-178.
286. Pallares J, Bussaglia E, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Sanchez-Verde L, Palacios J, Prat J, Matias-Guiu X. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue micro-array study with a comparison of four commercial antibodies in correlation with molecular abnormalities. *Mod Pathol* 2005; 18:719-727.
287. Pandolfi PP. PTEN and p53: who will get the upper hand? *Cancer Cell* 2003; 3(2):97-99.
288. Papageorgiou T, Stratakis CA. Ovarian tumours associated with multiple endocrine neoplasias and related syndromes (Carney complex, Peutz-Jeghers syndrome, von Hippel-Lindau disease, Cowden's disease). *Int J Gynecol Oncol* 2002; 12(4):337-347.
289. Parrot E, Butterworth M, Green A, White IN, Greaves P. Adenomyosis – a result of disordered stromal differentiation. *Am J Pathol* 2001; 159(2):623-630.
290. Parsons R. Phosphatases and tumorigenesis. *Curr Opin Oncol* 1998; 10(1):88-91.
291. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. *Int J Gynaecol Obstet* 1999; 65(3):243-249.

292. Peiffer SL, Hertzog TJ, Tribune DJ, Mitch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. *Cancer Res* 1995; 55:1922-1926.
293. Peiro G, Lohse P, Mayr D, Diebold J. Insulin like growth factor 1 receptor and PTEN protein expression in endometrial carcinoma. *Am J Clin Pathol* 2003; 120:78-85.
294. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. *Am J Pathol* 1999; 155(4):1253-1260.
295. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. *Am J Obstet Gynecol* 2004; 191(3):718-732.
296. Piura B, Meirovitz M, Bartfeld M, Yanai-Inbar I, Cohen Y. Peritoneal papillary serous carcinoma: study of 15 cases and comparison with stage III-IV ovarian papillary serous carcinoma. *J Surg Oncol* 1998; 68(3):173-178.
297. Piura B, Meirovitz M, Shmulman M, Yanai-Inbar I, Cohen Y, Dgani R. Uterine papillary serous carcinoma: study of 19 cases. *Eur J Obstet Gynecol Reprod Biol* 1998; 79(1):69-73.
298. Piura B, Bar-Dayana A, Cohen Y, Yanai-Inbar I, Glezerman M. Endometrial carcinoma in the south of Israel: study of 231 cases. *J Surg Oncol* 1997; 66(3):189-195.
299. Piura B, Rabinovich A, Yanai-Inbar I, Cohen Y, Glezerman M. Uterine sarcoma in the south of Israel: study of 36 cases. *J Surg Oncol* 1997; 64(1):55-62.
300. Plaxe SC, Saltzstein SL. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. *Gynecol Oncol* 1997; 65(1):8-12.
301. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. *Proc Natl Acad Sci U S A* 1999; 96(4):1563-1568.
302. Polaczek P, Kwan K, Campbell JL. GATC motifs may alter the conformation of DNA depending on sequence context and N6-adenine methylation status: possible implications for DNA-protein recognition. *Mol Gen Genet* 1998; 258(5):488-493.
303. Powell JL, Connor GP, Henderson GS. Androgen-producing, atypically proliferating endometrioid tumor arising in endometriosis. *South Med J* 2001; 94(4):450-453.
304. Prasad M, Wang H, Douglas W, Barakat RR, Ellenson LH. Molecular genetic characterisation of tamoxifen-associated endometrial cancer. *Gynecol Oncol* 2005; 96(1):25-31.
305. Prat AG. Nuclear ion channel activity is regulated by actin filaments. *Am J Physiol* 1996; 270:1532-1543.

306. Prefumo F, Todeschini F, Fulcheri E, Venturini PL. Epithelial abnormalities in cystic ovarian endometriosis. *Gynecol Oncol* 2002; 84(2):280-284.
307. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D et al. Ovarian carcinoma with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. *BMC Cancer* 2008; 8:17.
308. Quade BJ, Pinto AP, Howard DR, Peters WA, Crum CP. Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma. *Am J Pathol* 1999; 154:945-950.
309. Qian J, Shi Y. Bcl-2 and p53 protein expressions in the malignant transformation of ovarian endometriosis. *Chin J Pathol* 2001; 23(5):403-405.
310. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. Regulation of G1 progression by the PTEN tumour suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. *Proc Natl Acad Sci USA* 1999; 96(5):2110-2115.
311. Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, et al. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. *Oncogene* 1995; 10:2243-2246.
312. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. *Hum Pathol* 1994; 25:1075-1083.
313. Renan MJ. How many mutations are required for tumorigenesis? Implications from the human cancer data. *Mol Carcinog* 1993; 7:139-146.
314. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. *Obstet Gynecol* 1993; 82(2):181-186.
315. Rhei E, Bogomolny F, Federici MG, Maresco DL, Offit K, Robson ME, Saigo PE, Boyd J. Molecular genetic characterization of BRCA1 and BRCA2 linked hereditary ovarian cancers. *Cancer Res* 1998; 58(15):3193-3196.
316. Rhei E, Kang L, Bogomolny F, Federici MG, Borgen PI, Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. *Cancer Res* 1997; 57(17):3657-3659.
317. Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA et al. Identification of HER-2/ neu oncogene amplification in stage 1 endometrial carcinoma. *Mol Pathol* 1997; 10:823-831.
318. Ricci R, Komminoth P, Bannwart F, Torhorst J, Wight E, Heitz PU, Caduff RF. PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus. *Diag Molec Pathol* 2003; 12(2): 71-78.
319. Riedesel JM et al. Attitude about human papillomavirus vaccine among family physicians. *J Pediatr Adolesc Gynecol* 2005; 18:391-398

320. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. *Cancer Res* 1993; 53:5100-5103.
321. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. *Cancer Res* 1997; 57:4736-4738.
322. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge ME, Barrett JC, Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathological characteristics. *Clin Cancer Res* 1998; 4(12):3005-3010.
323. Risinger JI, Umar A, Boyer JC, Evans AC, Berchuck A, Kunkel TA, Barrett JC. Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. *Cancer Res* 1995; 55(23):5664-5669.
324. Rolitzky CD, Theil KS, McGaughey VR, Copeland LJ, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. *Int J Gynecol Pathol* 1999; 18:138-143
325. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. *N Eng J Med* 1996; 335(19):1413-1416.
326. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benmamin I, Rebbeck TR, Boyd J. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. *Am J Obstet Gynecol* 1998; 178(4):670-677.
327. Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. *Cell Tissue Res* 2005; 322:53-61.
328. Saffari B, Jones LA, El-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. *Cancer Res* 1999; 55:5693-5698.
329. Saga Y, Mizukami H, Suzuki M, Kohno T, Urabe M, Ozawa K, Sato I. Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells. *Clin Cancer Res* 2002; 8(5):1248-1252.
330. Saito M, Yamaguchi A, Goi T, Tsuchiyama T, Nakagawara G, Urano T, Shiku H, Furukawa K. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. *Oncology* 1999; 56:134-141.
331. Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. *Int J Cancer* 2000; 85(2):160-165.
332. Salvesen HB, MacDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA, Das S. Methylation of hMLH1 in a population based series of endometrial carcinomas. *Clin Cancer Res* 2000; 6:3607-3613.

333. Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S. Significance of PTEN alterations in endometrial carcinoma: a population based study of mutations, promoter methylation and PTEN protein expression. *Int J Oncol* 2004; 25:1615-1623.
334. Sanseverino F, D'Andrilli G, Petraglia F, Giordano A. Molecular pathology of ovarian cancer. *Analyt Quantit Cytol Histol* 2005; 27:121-124.
335. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima M, Siegal GP, Parker SL, Kohler MF, Berchuck A, Boyd J. Mutation of the *Ki-ras* proto-oncogene in human endometrial hyperplasia and carcinoma. *Cancer Res* 1993; 53:1906-1910.
336. Sasaki T, Sugiyama T, Nanjo H, Hoshi N, Murakami M, Sugita A, Takahashi M, Kawamura K, Ono I, Masuda H. Endometrioid adenocarcinoma arising from adenomyosis: report and immunohistochemical analysis of an unusual case. *Pathol Internatl* 2001; 51(4):308-313.
337. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, Seiki M. Expression of genes encoding type IV collagen degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. *Oncogene* 1992; 7:77-83.
338. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. *Cancer Res* 2000; 60:7052-7056.
339. Scambria G, Panici PB, Ferrandina G, Bttaglia F, Distefano M, D'Andrea G, et al. Significance of epidermal growth factor receptor expression in primary human endometrial cancer. *Int J Cancer* 1994; 56:26-30.
340. Schencken RS, Johnson JV, Riehl RM. C-myc proto-oncogene polypeptide expression in endometriosis. *Am J Obstet Gynecol* 1991; 164:1031-1036.
341. Schneider J, Jimenez E, Rodriguez F, Del Tanago JG. C-myc, c-erb-B2, nm23 and p53 expression in human endometriosis. *Oncol Rep* 1998; 5(1):49-52.
342. Schondorf T, Dostal A, Grabmann J, Gohring UJ. Single mutations of the PTEN gene in recurrent ovarian carcinomas. *J Soc Gynecol Investig* 2000; 7(5):313-316.
343. Schorge JO, Muto MG, Welch WR, Bandera CA, Rubin SC, Bell DA, Bercowitz RS, Mok SC. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. *J Natl Cancer inst.* 1998; 90(11):841-845.
344. Schwartz SM, Weiss NS, Daling JR, Newcomb PA, Liff JM, Gammon MD, Thompson WD, Watt JD, Armstrong BK, Weyer P, et al. Incidence of histologic subtypes of uterine sarcoma in relation to menstrual and reproductive history. *Int J Cancer* 1991; 49(3):362-367.

345. Scott RB, Te Linde RW, Wharton LR jr. Further studies on experimental endometriosis. *Am J Obstet Gynecol* 1953; 66(5):1082-1103.
346. Schiff M, Key CR, Gilliland FD, Becker TM. Ethnic differences in uterine corpus cancer incidence and mortality in New Mexico's American Indians, Hispanics and non-Hispanic whites. *Int J Epidemiol* 1997; 26(2):249-255.
347. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. In Scully RE, Poulsen HE, Sobin LH, eds. Histological typing of the female genital tract tumours. 2nd ed. Springer-Verlag 1994.
348. Seagusa M, Okayasu I. Bcl-2 is closely correlated with favourable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction reaction/loss of heterozygosity findings. *J Cancer Res Clin Oncol* 1997; 123(8):429-434.
349. Seleye-Fubara D, Uzoigwe SA. Uterine sarcomas in Port Harcourt, Nigeria: a 12 year clinicopathological study. *Afr Health Science* 2007; 7:10-13.
350. Semczuk A, Stenzel A, Baranowski W, Różyńska K, Cybulski M, Kostuch M, Jakowicki J, Wojcierowski J. Detection of human papillomavirus types 16 and 18 in human neoplastic endometrium: lack of correlation with established prognostic factors. *Oncol Rep* 2000; 7(4):905-910.
351. Semczuk A, Schneider-Stock R, Miturski R, Skomra D, Tomaszewski J, Roessner A, Jakowicki JA. RB protein expression in human endometrial carcinomas--an immunohistochemical study. *Pathol Res Pract* 2000; 196(1):41-46.
352. Semczuk A, Skomra D, Chyzynska M, Szewczuk W, Olcha P. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report. *Pathol Res Pract* 2008; 204:203-207.
- 353.** Semczuk A, Stenzel A, Baranowski W, Różyńska K, Cybulski M, Kostuch M, Jakowicki J, Wojcierowski J. Detection of human papillomavirus types 16 and 18 in human neoplastic endometrium: lack of correlation with established prognostic factors. *Oncol Rep* 2000; 7(4):905-910.
354. Semczuk A, Schneider-Stock R, Miturski R, Skomra D, Tomaszewski J, Roessner A, Jakowicki JA. RB protein expression in human endometrial carcinomas--an immunohistochemical study. *Pathol Res Pract* 2000; 196(1):41-46.
355. Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG, Parsons R, Sato T. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. *Int J Cancer* 1998; 77(5):684-688.
356. Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. *Oncogene* 1996; 13(1):1-7.

357. Sherman ME, Bur ME, Kurman RJ. P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. *Hum Pathol* 1995; 26(11):1268-1274.
358. Shondorf T, Gohring UJ, Roth G, Middel I, Becker M, Moser N, Valter MM, Hoopman M. Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients. *Eur J Clin Investig* 2003; 33:256-260.
359. Siegfried Z, Cedar H. DNA methylation: a molecular lock. *Current Biol* 1997;7(5):R305-307.
360. Silverberg S, Major F, Blessing J, Fetter B, Askin F, Liao SY, Miller A. Carcinosarcoma (Malignant Mixed Mesodermal tumor) of the uterus. A Gynecological Oncology Group pathological study of 203 cases. *Int J Gynecol Pathol* 1990; 9:1-19.
361. Silverman MB, Roch PC, Kho RM, Keeney GL, Li H, Podratz KC. Molecular and cytogenetic pretreatment risk assessment in endometrial carcinoma. *Gynecol Oncol* 2000; 77:1-7.
362. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, Palazzo JP, Fishel R, Goodfellow PJ. MLH1 promotor region methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. *Hum Mol Genet* 1999; 8:661-666.
363. Simpkins SB, Peiffer-Schneider S, Mutch DG, Gersell D, Goodfellow PJ. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. *Gynecol Oncol* 1998; 71(3):391-395.
364. Smid-Koopman E. Endometrial cancer from a molecular perspective. 2002; University of Rotterdam (unpublished dissertation).
365. Soloman D. The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA* 2002; 287(16):2114-2119.
366. Somigliana E, Vigano P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: A comprehensive overview and critical analysis of clinical and epidemiological evidence. *Gynecol Oncol* 2006; 101:331-341.
367. Sonoda Y, Saigo PE, Federici MG, Boyd J. Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin. *Gynecol Oncol* 2000; 76:226-229.
368. Stambolic V, Suzuki A, De la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumour suppressor PTEN. *Cell* 1998; 95:29-39.
369. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat Genet* 1997; 15:356-362.

370. Steed H, Chapman W, Laframboise S. Endometriosis-associated ovarian cancer: a clinicopathological review. *JOGC* 2004; 26(8):709-715.
371. Steenbergen RD, De Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ. HPV-mediated transformation of the anogenital tract. *J Clin Virol* 2005; 32:S25-S33.
372. Steinbrook R. The potential of human papillomavirus vaccines. *NEJM* 2006; 354:1109-1112.
373. Stern RC, Dash R, Bentley RC, Snyder MJ, Matthew J. Malignancy in endometriosis: frequency and comparison of ovarian and extra-ovarian types. *Int J Gynecol Pathol* 2001; 20(2):133-139.
374. Stocker H, Andjelkovic M, Oldman S, Laffargue M, Wymann MP, Hemmings BA, Hafen E. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. *Science* 2002; 295(5562):2088-2091.
375. Su TH, Chang JG, Perng LI, Chang CP, Wei HJ, Wang NM, Tsai CH. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer. *Gynecol Oncol* 2000; 76:193-199.
376. Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K, Nakamura T, Murata Y. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. *Am J Clin Pathol* 2001; 115:32-38.
377. Susuki C, Unoki M, Nakamura Y. Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes. *J Hum Genet* 2001; 46(3):155-157.
378. Swiersz LM. Role of endometriosis in cancer and tumor development. *Ann NY Acad Science* 2002; 955:281-292.
379. Takahashi K, Kurioko H, Inkoma M, Ozaki T, Kanasaki H et al. Benign or malignant ovarian neoplasms and ovarian endometriomas. *J Am Assoc Laparosc* 2001; 8(2):278-284.
380. Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, Weber BL, Livolsi VA, Furusato M, Rebane BA et al. Mutations of the BRCA1 gene in ovarian carcinomas. *Cancer Res* 1996; 56(12):2738-2741.
381. Takai N, Akizuki S, Nasu K, Etoh Y, Miyakawa I. Endometrioid adenocarcinoma arising from adenomyosis. *Gynecol Obstet Invest* 1999; 48(2):141-144.
382. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading and focal adhesions by tumor suppressor PTEN. *Science* 1998; 280:1614-1617.
383. Tamura M, Gu J, Takino T, Yamada KM. Tumour suppressor PTEN inhibition of cell invasion, migration and growth: differential involvement of focal adhesion kinase and p130Cas. *Cancer Res* 1999b; 59(2):442-449.
384. Tamura M, Gu J, Tran H, Yamada KM. PTEN and integrin signalling in cancer. *J Nat Cancer Instit* 1999a; 91:1820-1828.

385. Tanaka T, Umesaki N, Ogita S. Altered sensitivity to anti-endometriosis medicines in an adenomyosis patient with thyroid dysfunction. *Gynecol Endocrinol* 2000; 14(5):388-391.
386. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH. Mutations in PTEN are frequent in endometrial cancer but rare in other common gynaecological malignancies. *Cancer Res* 1997; 57:3935-3940.
387. Taskin M, Lallas TA, Shevchuk M, Barber HR. P53 expression in adenomyosis in endometrial carcinoma patients. *Gynecol Oncol* 1996; 62(2):241-246.
388. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. *Endocrin Rel Cancer* 2003; 10:203-208.
389. Thomas EJ, Campbell IG. Molecular genetic defects in endometriosis. *Gynecol Obstet Invest* 2000; 50(1):44-50.
390. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. *J Neuropathol Exp Neurol* 1998; 57(7):684-689.
391. Tonks NK. PTP1B: from the sidelines to the front lines! Review. *FEBS Lett* 2003; 546(1):140-148.
392. Torres J, Rodriguez J, Meyers MP, Valiente M, Graves JD, Tonks NK, Pulido R. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. *J Biol Chem* 2003; 278(33):30652-30660.
393. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. *Cancer Research* 1999; 59(10):2307-2312.
394. Trotman LC, Pandolfi PP. PTEN and p53: who will get the upper hand? *Cancer Cell* 2003; 3(2):97-99.
395. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. *Oncogene* 1998; 16(26):3397-3402.
396. Tsou HC, Ping XL, Xie XX, Gruener AC, Zhang H, Nini R, Swisshelm K, Sybert V, Diamond TM, Sutphen R, Peacocke M. The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC1/TEP1. *Hum Genet* 1998; 102(4):467-473.
397. Turbiner J, Moreno-Bueno G, Dahiya S, Sanchez-Estevez C, Hardisson D, Prat J, Oliva E, Palacios J. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. *Mod Pathol* 2008; 21:925-936.

398. Uduwela AS, Perera MA, Aiqing L, Fraser IS. Endometrial-myometrial interface: relationship to adenomyosis and changes in pregnancy. *Obstet Gynecol Surv* 2000; 55(6):390-400.
399. Uegaki K, Kanamori Y, Kigawa J, Kawaguchi W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H, Terakawa N. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. *Oncol Rep* 2005; 14:389-392.
400. Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR1, two genes involved in the PTEN signalling pathway. *Oncogene* 2001; 20(33):4457-4465.
401. Varma R, Rollason T, Gupta JK, Mher ER. Endometriosis and the neoplastic process. *Reproduction* 2004; 127(3):293-304.
402. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, Luchini L, Crosignani PG. Endometriosis and ovarian cancer. *Am J Obstet Gynecol* 1993; 169(1):181-182.
403. Viganò P, Somigliana E, Chiodo I, Abbiati A, Vercellini P. Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. *Human Reprod Update* 2006; 12:77-89.
404. Villa LL, Costa RLR, Petta CA. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol* 2005; 6:271-278.
405. Waite KA, Eng C. Protean PTEN: form and function. *Am J Hum Genet* 2002; 70(4):829-844.
406. Walker CL. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. *Rec Prog Horm Res* 2002; 57:277-294.
407. Wang Y, Kristensen GB, Helland A, Nesland JM, Boreesen-Dale AL, Holm R. Protein expression and prognostic value of genes in the erb-b signalling pathway in advanced ovarian carcinomas. *Am J Clin Pathol* 2005; 124(3):392-401.
408. Wang PH, Yang TS, Lee WL, Chao HT, Chang SP, Yuam CC. Treatment of infertile women with adenomyosis with a conservative microsurgical technique and a gonadotropin-releasing hormone agonist. *Fertil Steril* 2000; 73(5):1061-1062.
409. Wang ZJ, Taylor F, Churchman M, Norbury G, Tomlinson I. Genetic pathways of colorectal carcinogenesis rarely involves the PTEN and LKB1 genes outside the inherited hamartoma syndromes. *Am J Pathol* 1998; 153(2):363-366.
410. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. *Cancer* 1993; 71:2628-2637.

411. Wells M. Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation. *Int J Gynecol Pathol* 2004; 23(4):316-320.
412. Whitley BR, Beaulieu LM, Carter JC, Church FC. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. *Gynecol Oncol* 2007; 104:470-479.
413. Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC. Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-IB, PTP-alpha expression. *Gynecol Oncol* 1996; 61(2):233-240.
414. Wu H, Wang S, Weng D, Xing H, Song X, Zhu T, Xia X, Weng Y, Xu G, Meng L, Zhou J, Ma D. Reversal of malignant phenotype of ovarian cancer A2780 cells through tranfection with wild-type PTEN gene. *Cancer Letters* 2008; 271(2):205-214.
415. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumour suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. *Proc Natl Acad Sci USA* 1998; 95(26):15587-15591.
416. Xu Z, Stokoe D, Kane LP, Weiss A. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. *Cell Growth Diff* 2002; 13(7):285-296.
417. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signalling, growth, migration and apoptosis. *J Cell Sci* 2001; 114:2375-2382.
418. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer. miR214 induces cell survival and cisplatin resistance by targeting PTEN. *Cancer Res* 2008; 68:425-433.
419. Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI et al. Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. *Int J Oncol* 1998; 13(1):101-105.
420. Yoshinaga K, Sasano H, Furukawa T, Yamakawa H, Yuki M, Sato S, Yajima A, Horii A. The PTEN, BAX, and IGF-IIR genes are mutated in endometrial atypical hyperplasia. *Jpn J Cancer Res* 1998; 89(10):985-990.
421. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-HO kinase/Akt pathway in human ovarian cancer. *Oncogene* 2000; 19(19):2324-2330.
422. Yuan JP, Wang GH, Ling H, Su Q, Yang YH, Song Y, Tang RJ, Liu Y, Huang C. Diallyl disulfide-induced G2/M arrest of human gastric cancer MGC803 cells involves activation of p38 MAP kinase pathways. *World J Gastroenterol* 2004; 10(18):2731-2734.

423. Zaloudek C, Norris HJ. Mesenchymal tumors of the uterus. In: Kurman RJ, ed. *Blaustein's pathology of the female genital tract*. New York: Springer-Verlag, 4th edition, 1994; 486-528.
424. Zelmanowicz A, Hildesheim A, Sherman M, Sturgeon S, Kurman R, Barret R, Berman M, Mortel R, Twiggs L, Wilbanks G, Brinton L. Evidence for a common etiology for endometrial carcinomas and malignant mixed Mullerian tumors. *Gynecol Oncol* 1998; 69:253-257.
425. Zhai YL, Nikaido T, Orii A, Horiuchi A, Toki T, Fujii S. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. *Gynecol Oncol* 1999; 75(3):453-459.
426. Zhang H, Zhao X, Liu S, Li J, Wen Z, Li M. 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. *Mol Cell Endocrinol* 2010; 317:31-43.
427. Zheng J, Kulp SK, Zhang Y, Sugimoto Y, Dayton MA, Govindan MV, Brueggemeier RW, Lin YC. 17 beta estradiol regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells. *Anticancer Res* 2000; 20(1A):11-19.
428. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. P53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. *Gynecol Oncol* 1996; 61:167-174.